KR100671036B1 - 오스테오프로테게린 리간드 활성을 하향-조절하는 방법 - Google Patents

오스테오프로테게린 리간드 활성을 하향-조절하는 방법 Download PDF

Info

Publication number
KR100671036B1
KR100671036B1 KR1020017003379A KR20017003379A KR100671036B1 KR 100671036 B1 KR100671036 B1 KR 100671036B1 KR 1020017003379 A KR1020017003379 A KR 1020017003379A KR 20017003379 A KR20017003379 A KR 20017003379A KR 100671036 B1 KR100671036 B1 KR 100671036B1
Authority
KR
South Korea
Prior art keywords
opgl
ser
gly
leu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017003379A
Other languages
English (en)
Korean (ko)
Other versions
KR20010085807A (ko
Inventor
토르벤 할키에르
제스퍼 하아닝
Original Assignee
파멕사 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파멕사 에이/에스 filed Critical 파멕사 에이/에스
Publication of KR20010085807A publication Critical patent/KR20010085807A/ko
Application granted granted Critical
Publication of KR100671036B1 publication Critical patent/KR100671036B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fodder In General (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020017003379A 1998-09-15 1999-09-13 오스테오프로테게린 리간드 활성을 하향-조절하는 방법 Expired - Fee Related KR100671036B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA199801164 1998-09-15
DKPA199801164 1998-09-15
US10289698P 1998-10-02 1998-10-02
US60/102,896 1998-10-02

Publications (2)

Publication Number Publication Date
KR20010085807A KR20010085807A (ko) 2001-09-07
KR100671036B1 true KR100671036B1 (ko) 2007-01-18

Family

ID=26065320

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017003379A Expired - Fee Related KR100671036B1 (ko) 1998-09-15 1999-09-13 오스테오프로테게린 리간드 활성을 하향-조절하는 방법

Country Status (24)

Country Link
US (2) US6645500B1 (enExample)
EP (1) EP1114166B1 (enExample)
JP (1) JP2002525060A (enExample)
KR (1) KR100671036B1 (enExample)
CN (1) CN1318105A (enExample)
AT (1) ATE291628T1 (enExample)
AU (1) AU754971B2 (enExample)
CA (1) CA2343654A1 (enExample)
CZ (1) CZ2001789A3 (enExample)
DE (1) DE69924392T2 (enExample)
EE (1) EE200100149A (enExample)
ES (1) ES2239457T3 (enExample)
HK (1) HK1040261A1 (enExample)
HR (1) HRP20010188A2 (enExample)
HU (1) HUP0103578A3 (enExample)
ID (1) ID28386A (enExample)
IL (2) IL141588A0 (enExample)
NO (1) NO20011304L (enExample)
NZ (1) NZ510508A (enExample)
PL (1) PL196790B1 (enExample)
PT (1) PT1114166E (enExample)
SK (1) SK3062001A3 (enExample)
TR (1) TR200100737T2 (enExample)
WO (1) WO2000015807A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020101145A1 (ko) * 2018-11-12 2020-05-22 조선대학교 산학협력단 Rankl의 돌연변이체, 및 이를 포함하는 골다공증 예방 또는 치료용 약학 조성물
WO2025165132A1 (ko) * 2024-01-29 2025-08-07 주식회사 아크젠바이오사이온스 Rankl의 돌연변이체 및 이를 포함하는 백신 조성물

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO128635A2 (ro) * 1997-04-16 2013-07-30 Amgen Inc. Anticorp sau fragment al acestuia care se leagă la opgbp şi utilizarea acestuia, utilizarea unei forme solubile de odar, şi metodă de identificare a unui compus care descreşte activitatea opgbp
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
ES2239457T3 (es) * 1998-09-15 2005-09-16 Pharmexa A/S Procedimiento para regular a niveles mas bajos la actividad de ligando de osteoprotegerina.
GB9908263D0 (en) * 1999-04-13 1999-06-02 Binding Site The Limited Eliciting improved immune responses
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
EP1207873B1 (en) * 1999-07-28 2009-11-18 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
AU7615600A (en) * 1999-09-27 2001-04-30 Eli Lilly And Company Osteoclast differentiation factor regulatory region
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
KR20080017471A (ko) * 2000-02-21 2008-02-26 파멕사 에이/에스 아밀로이드의 하향-조절을 위한 신규한 방법
ME00183B (me) * 2000-02-21 2011-02-10 Pharmexa As Novi postupak za deregulaciju amiloida
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
MXPA02008144A (es) * 2000-02-23 2002-11-29 Amgen Inc Agentes de enlace selectivos antagonistas de la proteina de enlace de osteoprotegerina.
US20030215450A1 (en) * 2000-05-26 2003-11-20 Blake Simon M Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
AU2001288342A1 (en) * 2000-08-21 2002-03-04 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
WO2002024228A1 (fr) * 2000-09-21 2002-03-28 Center For Advanced Science And Technology Incubation, Ltd. Méthode de régulation de la formation d'ostéoclastes
DE01973455T1 (de) 2000-09-22 2004-04-22 Immunex Corp., Seattle Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
WO2002080955A1 (en) * 2001-03-22 2002-10-17 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
AU2002253133B2 (en) 2001-04-03 2008-02-28 Societe Des Produits Nestle S.A. Osteoprotegerin in milk
DK2270052T3 (en) * 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US20030109444A1 (en) * 2001-10-12 2003-06-12 Jonathan Lam Bone anti-resorptive compounds
JP4336467B2 (ja) * 2001-10-15 2009-09-30 株式会社林原生物化学研究所 破骨細胞形成抑制因子の産生を調節し得る物質のスクリーニング方法
EP1560843A4 (en) * 2002-01-04 2006-09-06 Xencor Inc NEW VARIANTS OF RANKL PROTEIN
WO2003057856A2 (en) 2002-01-04 2003-07-17 Xencor Dominant negative proteins and methods thereof
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
JP4761710B2 (ja) * 2002-04-05 2011-08-31 アムジェン インコーポレイテッド 選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7462700B2 (en) 2002-12-10 2008-12-09 Schering-Plough Animal Health Corporation Canine RANKL and methods for preparing and using the same
KR20070058426A (ko) * 2004-06-02 2007-06-08 사이토스 바이오테크놀로지 아게 비-인간 ｔｎｆ-펩티드의 담체 콘쥬게이트의 의학적 용도
US20080107597A1 (en) * 2006-01-12 2008-05-08 Anaptys Biosciences, Inc. Isolation of antibodies that cross-react and neutralize rankl originating from multiple species
WO2008088594A2 (en) * 2007-01-12 2008-07-24 Anaptysbio, Inc. Isolation of antibodies that cross-react and neutralize rankl orginating from multiple species
CN101434656B (zh) * 2007-11-16 2011-12-14 首都医科大学 Opg-hsp70融合蛋白的制备方法及用途
JP5866601B2 (ja) * 2008-06-18 2016-02-17 ザ テキサス エーアンドエム ユニバーシティ システムＴｈｅ Ｔｅｘａｓ Ａ＆Ｍ Ｕｎｉｖｅｒｓｉｔｙ Ｓｙｓｔｅｍ 医薬組成物の製造方法
WO2011128892A2 (en) * 2010-04-12 2011-10-20 Protea Vaccine Technologies Ltd. Modified forms of pneumococcal surface immunogenic protein b (psipb)
CN107286245B (zh) * 2016-04-11 2021-10-08 北京普纳生物科技有限公司 Pd-l1和pd-l2重组蛋白及其用途
CN107286244B (zh) * 2016-04-11 2021-10-08 北京普纳生物科技有限公司 抗免疫检查点pd-l1和pd-l2肿瘤疫苗
CN108498786A (zh) * 2018-02-13 2018-09-07 南昌大学第二附属医院 载骨保护素的缓释纳米粒及其制备方法和应用
WO2024054566A1 (en) * 2022-09-07 2024-03-14 The Regents Of The University Of California Treatment of cancer by blockade of osteoprotegerin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
AU7639994A (en) 1993-08-27 1995-03-21 Dow Chemical Company, The Process for the separation of enantiomers
EP0755444A4 (en) * 1994-04-01 1998-01-14 Univ Utah MOLECULAR CLONING AND EXPRESSION OF AN INDUCTIBLE PROTEASOME ACTIVATOR BY INTERFERON GAMMA
US6340459B1 (en) * 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
DE122010000046I1 (de) * 1996-12-13 2011-05-05 Schering Corp Oberflächenantigene aus Säugern
DE951551T1 (de) * 1996-12-23 2000-09-14 Immunex Corp., Seattle Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
RO128635A2 (ro) * 1997-04-16 2013-07-30 Amgen Inc. Anticorp sau fragment al acestuia care se leagă la opgbp şi utilizarea acestuia, utilizarea unei forme solubile de odar, şi metodă de identificare a unui compus care descreşte activitatea opgbp
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
ES2239457T3 (es) * 1998-09-15 2005-09-16 Pharmexa A/S Procedimiento para regular a niveles mas bajos la actividad de ligando de osteoprotegerina.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020101145A1 (ko) * 2018-11-12 2020-05-22 조선대학교 산학협력단 Rankl의 돌연변이체, 및 이를 포함하는 골다공증 예방 또는 치료용 약학 조성물
WO2025165132A1 (ko) * 2024-01-29 2025-08-07 주식회사 아크젠바이오사이온스 Rankl의 돌연변이체 및 이를 포함하는 백신 조성물

Also Published As

Publication number Publication date
NZ510508A (en) 2005-05-27
AU754971B2 (en) 2002-11-28
NO20011304D0 (no) 2001-03-14
CA2343654A1 (en) 2000-03-23
EE200100149A (et) 2002-08-15
AU5617399A (en) 2000-04-03
WO2000015807A1 (en) 2000-03-23
EP1114166A1 (en) 2001-07-11
ID28386A (id) 2001-05-17
IL141588A (en) 2008-07-08
ATE291628T1 (de) 2005-04-15
KR20010085807A (ko) 2001-09-07
JP2002525060A (ja) 2002-08-13
CN1318105A (zh) 2001-10-17
HUP0103578A2 (hu) 2002-01-28
CZ2001789A3 (cs) 2001-08-15
EP1114166B1 (en) 2005-03-23
PL346698A1 (en) 2002-02-25
IL141588A0 (en) 2002-03-10
ES2239457T3 (es) 2005-09-16
US6645500B1 (en) 2003-11-11
PT1114166E (pt) 2005-08-31
HRP20010188A2 (en) 2002-04-30
NO20011304L (no) 2001-05-15
PL196790B1 (pl) 2008-01-31
US20040115199A1 (en) 2004-06-17
HUP0103578A3 (en) 2005-11-28
TR200100737T2 (tr) 2001-07-23
DE69924392D1 (de) 2005-04-28
HK1040261A1 (zh) 2002-05-31
DE69924392T2 (de) 2006-03-09
SK3062001A3 (en) 2002-02-05

Similar Documents

Publication Publication Date Title
KR100671036B1 (ko) 오스테오프로테게린 리간드 활성을 하향-조절하는 방법
KR100750695B1 (ko) Ｇｄｆ-8 활성을 하향-조절하는 방법
CZ2002182A3 (cs) Kompozice pro vyvolání imunitní odpovědi, její použití, kit, fúzní protein, nukleová kyselina a expresní vektor
US20070184023A1 (en) Method for down-regulation of vegf
AU2006312847A1 (en) Therapeutic vaccines targeting HMGB1
NZ527873A (en) Vaccine
AU2002233560A1 (en) Vaccine
US6746669B1 (en) Method for down-regulating IL5 activity
US20020172673A1 (en) Method for down-regulating IgE
US20080253993A1 (en) Immunogenic Egfr Peptides Comprising Foreign T Cell Stimulating Epitope
WO2009003889A2 (en) Immunogenic analogues of rankl
CN101260152A (zh) 负调节Osteoprotegerin配体活性的方法
KR20060015595A (ko) 해독된 ｔｎｆ 및 그의 제조 방법
EP1541587A2 (en) Method for down-regulating osteoprotegerin ligand activity
WO2008040759A1 (en) Method for down-regulation of cripto

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20100112

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20100112